View clinical trials related to Lymphoma, T-Cell, Peripheral.
Filter by:This program is intended to provide access to sugemalimab for participants with R/R ENKTL, after their disease failed to respond to prior treatment regimen(s), preceding marketing authorization by the local regulatory agency.